Jacques Robert
| Jacques Robert | |
|---|---|
| Born | 1949 |
| 🏳️ Nationality | French |
| 🎓 Alma mater | University of Bordeaux; University of Strasbourg |
| 💼 Occupation | |
| Known for | Anticancer drug pharmacology; Tumour resistance; Pharmacogenetics; Cancer genomics |
Jacques Robert (born 1949) is an academic French cancer researcher. As a specialist in anticancer pharmacology, he headed the biochemistry laboratory of the Institut Bergonié in Bordeaux for nearly forty years and has been professor emeritus at the University of Bordeaux since 2018.
His research focuses on predicting anticancer drug activity, tumour drug resistance, pharmacogenetics and cancer genomics. His h-index is 62.[1]
Biography
Education
Jacques Robert received an M.D. from the University of Bordeaux in 1974, followed by a Ph.D. in science from the University of Strasbourg in 1978. He subsequently served as faculty assistant (1974), research associate (1978), assistant professor (1987) and was appointed full professor and hospital practitioner in 1994.
Academic and hospital career
He spent most of his career at the University of Bordeaux and at the Institut Bergonié, where he ran the biochemistry laboratory. He became professor emeritus in 2018.
He is a member of INSERM Unit 1312 and currently works on cancer genomics using public databases of human cancer cell lines and human tumours, including:
- the National Cancer Institute
- the Cancer Cell Line Encyclopedia (CCLE)
- Genomics of Drug Sensitivity in Cancer (GDSC)
- The Cancer Genome Atlas (TCGA)
In 2014, he spent a sabbatical semester at the National Cancer Institute in Bethesda in the team of Yves Pommier.
Research
Robert’s research covers the identification of tools for predicting anticancer drug activity, including:
- pharmacokinetics
- metabolism of anticancer agents
- tumour resistance to treatment
- cellular and molecular pharmacology
- pharmacogenetics
- cancer genomics
He has contributed to studies of:
- anthracyclines
- camptothecin derivatives
- modulators of multidrug resistance
- tyrosine kinase receptor inhibitors
He is the author or co-author of more than 250 original articles and around 100 review papers. He is part of the INSERM Unit 1312 team “Reprogramming Tumour Activity and its Associated Microenvironment” at BRIC Bordeaux.[2]
Institutional service
Robert served as president of the French Cancer Society in 2004–2005, where he initiated several training programmes for oncology residents.
He has held positions on numerous committees, including:
- Ligue contre le cancer National League against Cancer
- INSERM
- ARC Foundation
- INCa
- French National Council of Universities
He is the editor of the book series L’innovation thérapeutique en cancérologie[3] and deputy editor of the series Thérapies ciblées du cancer.[4]
He has also served on the editorial boards of:
- Critical Reviews in Oncology/Hematology
- European Journal of Cancer
- Cancer Chemotherapy and Pharmacology
- Fundamental and Clinical Pharmacology
- Journal of Chemotherapy
- Bulletin du Cancer[5]
- Innovation et thérapeutique en oncologie[6]
Books
Specialist works
- Signalisation cellulaire et cancer, Lavoisier, 2nd ed., 2018
- Pharmacologie des cancers, Lavoisier, 2014
- Oncogenèse et développement des cancers, Lavoisier, 2020
- Ciblage thérapeutique en oncologie, Elsevier-Masson, 2023[7]
General audience
- Cancer, l’ennemi intérieur, CNRS Éditions, 2024[8]
Scientific integrity
Selected bibliography
- Robert J. Academic freedom and scientific self-censorship. Innovations et Thérapeutiques en Oncologie 2025; 11: 8–11. DOI: 10.1684/ito.2025.490
- Robert J. The myth of longevity: from dream to unreality. Bulletin du Cancer 2024; 111: 802–811. DOI: 10.1016/j.bulcan.2024.04.008
- Barrière J, Frank F, Besançon L, Samuel A, Saada V, Billy E, Al-Ahmad A, Seitz-Polski B, Robert J. Scientific integrity requires publishing rebuttals and retracting problematic papers. Stem Cell Reviews and Reports 2023; 19: 568–572. doi:10.1007/s12015-022-10465-2
- Fessart D, Villamor I, Chevet E, Delom F, Robert J. Integrative analysis of genomic and transcriptomic alterations of AGR2 and AGR3 in cancer. Open Biology 2022; 12: 220068. doi:10.1098/rsob.220068
- Luna A, Elloumi F, Varma S, Wang Y, Rajapakse VN, Aladjem MI, Robert J, Sander C, Pommier Y, Reinhold WC. CellMiner Cross-Database (CellMinerCDB) version 1.2: exploration of patient-derived cancer cell line pharmacogenomics. Nucleic Acids Research 2021; 49(D1): D1083–D1093. doi:10.1093/nar/gkaa968
- Le Morvan V, Richard É, Cadars M, Fessart D, Broca-Brisson L, Auzanneau C, Pasquies A, Modesto A, Lusque A, Mathoulin-Pélissier S, Lansiaux A, Robert J. Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma. British Journal of Cancer 2020; 123: 772–784. doi:10.1038/s41416-020-0932-5
References
External links
- Google Scholar profile
- Author page – Éditions Eyrolles
- BRIC Bordeaux team
- Impostures en cancérologie – H&O
- Cancer, l’ennemi intérieur – CNRS Éditions
- Science, la citadelle assiégée – FYP
Category:1949 births Category:Living people Category:French oncologists Category:French pharmacologists Category:Cancer researchers Category:Academic staff of the University of Bordeaux Category:University of Bordeaux alumni Category:University of Strasbourg alumni Category:French medical researchers
This article "Jacques Robert (oncologist)" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Jacques Robert (oncologist). Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
